ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
Abstract ALK positive non-small cell lung cancer is highly responsive to ALK inhibitors such as crizotinib, but drug resistance typically develops within a year of treatment. In this study we investigated whether IGF-1R is an independent druggable target in ALK-positive lung cancer cells. We confirm...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-017-14289-w |